Alnylam Pharmaceuticals, Inc. <ALNY.O>: BMO initiates coverage with outperform rating; price target $318
ALNY•Related News
BioMarin Pharmaceutical Inc. <BMRN.O>: BMO initiates coverage with outperform rating; price target $98
BMRN•
Estee Lauder rises on robust annual profit outlook
EL•
Okta, Inc. <OKTA.O>: Truist Securities Raises Target Price to $165 From $120
OKTA•
Palladyne AI partners with Orkid Tech to integrate autonomy software into fixed-wing UAVs
PDYN•
Estee Lauder forecasts strong annual profit on resilient fragrance demand
EL•